Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
0.6749
-0.0441 (-6.13%)
Jul 24, 2025, 2:14 PM - Market open
Relmada Therapeutics Stock Forecast
RLMD's stock price has decreased by -83.22% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts that cover Relmada Therapeutics stock have a consensus rating of "Buy" and an average price target of $5, which forecasts a 640.96% increase in the stock price over the next year. The lowest target is $1 and the highest is $13.
Price Target: $5 (+640.96%)
Analyst Consensus: Buy
* Price targets were last updated on Dec 5, 2024.
Analyst Ratings
The average analyst rating for Relmada Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Buy → Hold Downgrades $23 → $1 | Buy → Hold | Downgrades | $23 → $1 | +48.19% | Dec 5, 2024 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $10 → $1 | Buy → Hold | Downgrades | $10 → $1 | +48.19% | Dec 4, 2024 |
| Jefferies | Jefferies | Hold → Strong Buy Upgrades $3.5 → $13 | Hold → Strong Buy | Upgrades | $3.5 → $13 | +1,826.50% | Sep 17, 2024 |
| Goldman Sachs | Goldman Sachs | Hold → Strong Sell Downgrades $3 → $2 | Hold → Strong Sell | Downgrades | $3 → $2 | +196.38% | Jun 5, 2024 |
| Mizuho | Mizuho | Strong Buy Reiterates $26 | Strong Buy | Reiterates | $26 | +3,752.99% | Jun 15, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.97
from -2.65
EPS Next Year
-1.73
from -1.97
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.03 | -1.79 | -1.61 | ||
| Avg | -1.97 | -1.73 | -1.56 | ||
| Low | -1.89 | -1.67 | -1.50 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.